drugset / Trial / NCT01560052

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)

NCT01560052

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the long-term efficacy and safety of low dose oral methylprednisolone compared to matching placebo, on a background of routine RAS inhibitor therapy, in preventing kidney events in patients with IgA nephropathy and features suggesting a high risk of progression.

Timeline

Start
2012-05-05
Primary completion
2021-07-23
Completion
2021-07-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 0.4 mg/kg Oral
Comparator Methylprednisolone Other / unclassified 0.8 mg/kg Oral